ACRV (Acrivon Therapeutics) Bathi resik saben saham (EPS TTM)

Acrivon Therapeutics (ACRV) dominates targeted oncology through its AP3 AI platform, outpacing industry behemoths. Innovations in precision proteomics and the launch of CHK1/2 inhibitors are transforming diagnostics. Flexibility is ensured by the full outsourcing of production and trials. The 12-month rolling income per unit illustrates financial stability, where -1.91 describes the current status of the metric.

ACRV Bathi resik saben siji saham sajrone rolas wulan pungkasan acrivon.com (28.04.2023 - 15.11.2026)

Rincian metrik lan analitis perusahaan Acrivon Therapeutics (ACRV)

- kuotasi saiki lan rata-rata prakiraan nilai:

Bagan rega Acrivon|ACRV - Prakiraan gabungan firma investasi

- indikator valuasi pasar bisnis:

Kapitalisasi pasar Acrivon Therapeutics, Inc.|ACRV - Total Nilai Perusahaan

- rincian valuasi buku bisnis:

Aset Bersih saben Siji Saham Acrivon Therapeutics|ACRV - Ekuitas Perusahaan|Rasio Kapitalisasi marang Aset Bersih acrivon.com|ACRV - Total Aset Perusahaan

- rincian utang lan likuiditas:

Utang marang Ekuitas Acrivon Therapeutics|ACRV - Rasio tanggungan utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Acrivon Therapeutics|ACRV - Kewajiban utang agregat|Rasio utang marang kapitalisasi buku Acrivon Therapeutics, Inc.|ACRV - Utang jangka dawa|Utang jangka cendhak perusahaan Acrivon Therapeutics|Rasio cepet acrivon.com

- data bathi lan kelipatan valuasi:

ACRV - Penghasilan resik|Bathi sing dikarepake Acrivon Therapeutics|ACRV - Kapitalisasi marang bathi|Rega marang bathi mangsa ngarep Acrivon|ACRV - Rasio rega marang bathi tumrap wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Acrivon Therapeutics, Inc.|ACRV - Bathi sadurunge bunga, pajak, lan amortisasi|Bathi resik saben saham (EPS TTM) Acrivon Therapeutics|ACRV - Bathi resik saben saham sajroning taun lumaku|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan acrivon.com|ACRV - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Acrivon Therapeutics

- data pendapatan lan penerimaan dodolan:

ACRV - Pendapatan lan volume dodolan|Prakiraan volume dodolan Acrivon Therapeutics Inc|ACRV - Kapitalisasi marang pendapatan|Rasio rega marang prakiraan pendapatan Acrivon Pharma|ACRV - Dinamika pendapatan YoY sajrone rolas wulan kepungkur

Analisis umum perusahaan:ACRV - Acrivon Pharma

Earnings per share (EPS TTM) measures the portion of profit allocated to each ordinary share over a year. The calculation excludes the impact of equity dilution, demonstrating the actual efficiency of income generation. By analyzing the net income per share over the last 12 months, an investor assesses the pace of business recovery. For Acrivon Therapeutics (ACRV), this metric reflects the financial impact of implementing AI in the search for targeted drugs. Strategic alliances in oncology directly determine future profit capitalization.

Pesaing utama

NVCR - Bathi saben saham sajrone rolas wulan pungkasan|DRTS (Alpha Tau Medical) - Bathi saben saham sajrone 12 wulan pungkasan|FBIO: Bathi resik saben saham (EPS TTM)|Bathi resik saben siji saham sajrone rolas wulan pungkasan Allarity (ALLR)